Arrowhead Research | ARWR - Interest Expense On Debt

Stock Price
63.59
Daily Change
-0.27 -0.42%
Monthly
-5.93%
Yearly
219.55%
Q1 Forecast
61.62

Arrowhead Research reported $22.5M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Anika Therapeutics 189.44M 1.76M Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
Heron Therapeutics USD 500K 900K Sep/2024
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Ligand Pharmaceuticals USD 910K 243K Sep/2025
Merck USD 412M 85M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Novartis USD 281M 8M Sep/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
TG Therapeutics USD 6.72M 4K Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 7.66M 578K Sep/2025